www.finanzen.net bietet Finanznachrichten zum weltweiten Boersengeschehenhttp://www.finanzen.netde-deSmartHouse Media GmbHhttp://finanzen.net/images/finanzen_net.gifhttp://www.finanzen.nethttp://www.finanzen.net/nachricht/Alnylam-to-Webcast-Presentation-at-the-22nd-Annual-ROTH-OC-Growth-Stock-Conference-754738 <style type="text/css"> <!-- .bwtextaligncenter {text-align: center} --> </style> Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that management will present a company ...http://www.finanzen.net/nachricht/Alnylam-to-Webcast-Presentation-at-the-22nd-Annual-ROTH-OC-Growth-Stock-Conference-754738http://www.finanzen.net/nachricht/Alnylam-to-Webcast-Presentation-at-Cowen-and-Company-s-30th-Annual-Health-Care-Conference-751554 <style type="text/css"> <!-- .bwtextaligncenter {text-align: center} --> </style> Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that management will present a company ...http://www.finanzen.net/nachricht/Alnylam-to-Webcast-Presentation-at-Cowen-and-Company-s-30th-Annual-Health-Care-Conference-751554http://www.finanzen.net/nachricht/Alnylam-Provides-Update-on-Ongoing-Litigation-Regarding-the-Tuschl-I-Patent-Series-751006 <style type="text/css"> <!-- .bwtextaligncenter {text-align: center} --> </style> Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that the company and Max Planck have asked ...http://www.finanzen.net/nachricht/Alnylam-Provides-Update-on-Ongoing-Litigation-Regarding-the-Tuschl-I-Patent-Series-751006http://www.finanzen.net/nachricht/Alnylam-to-Webcast-RNAi-Roundtable-on-Thursday-March-4-2010-749109 <style type="text/css"> <!-- .bwtextaligncenter {text-align: center} --> </style> Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that it will be hosting a virtual RNAi ...http://www.finanzen.net/nachricht/Alnylam-to-Webcast-RNAi-Roundtable-on-Thursday-March-4-2010-749109http://www.finanzen.net/nachricht/Alnylam-Pharmaceuticals-Reports-Fourth-Quarter-and-2009-Financial-Results-748657 <style type="text/css"> <!-- .bwcellpaddingbottom1 {padding-bottom: 2.0px} .bwcellpaddingbottom3 {padding-bottom: 4.0px} .bwcellpaddingleft0 {padding-left: 0.0px} .bwcellpaddingright0 {padding-right: 0.0px} .bwcellparagraphmargin {margin-bottom: 0px; ...http://www.finanzen.net/nachricht/Alnylam-Pharmaceuticals-Reports-Fourth-Quarter-and-2009-Financial-Results-748657http://www.finanzen.net/nachricht/Regulus-Therapeutics-and-GlaxoSmithKline-Establish-New-Collaboration-to-Develop-and-Commercialize-microRNA-Therapeutics-Targeting-miR-122-748276 <style type="text/css"> <!-- .bwtextaligncenter {text-align: center} --> </style> Regulus Therapeutics Inc. today announced the establishment of a new collaboration with GlaxoSmithKline (GSK) to develop and commercialize ...http://www.finanzen.net/nachricht/Regulus-Therapeutics-and-GlaxoSmithKline-Establish-New-Collaboration-to-Develop-and-Commercialize-microRNA-Therapeutics-Targeting-miR-122-748276http://www.finanzen.net/nachricht/Alnylam-Selected-as-One-of-the-50-Most-Innovative-Companies-in-the-World-by-MIT-s-Technology-Review-747461 <style type="text/css"> <!-- .bwtextaligncenter {text-align: center} --> </style> Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that it has been selected as one of MIT ...http://www.finanzen.net/nachricht/Alnylam-Selected-as-One-of-the-50-Most-Innovative-Companies-in-the-World-by-MIT-s-Technology-Review-747461http://www.finanzen.net/nachricht/Alnylam-Initiates-Phase-IIb-Clinical-Trial-of-ALN-RSV01-in-Adult-Lung-Transplant-Patients-Infected-with-Respiratory-Syncytial-Virus-RSV-Infection-745840 <style type="text/css"> <!-- .bwtextaligncenter {text-align: center} --> </style> Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that it has initiated a Phase IIb trial ...http://www.finanzen.net/nachricht/Alnylam-Initiates-Phase-IIb-Clinical-Trial-of-ALN-RSV01-in-Adult-Lung-Transplant-Patients-Infected-with-Respiratory-Syncytial-Virus-RSV-Infection-745840http://www.finanzen.net/nachricht/Alnylam-to-Webcast-Conference-Call-Discussing-Fourth-Quarter-and-2009-Financial-Results-744973 <style type="text/css"> <!-- .bwtextaligncenter {text-align: center} --> </style> Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that it will report financial results for ...http://www.finanzen.net/nachricht/Alnylam-to-Webcast-Conference-Call-Discussing-Fourth-Quarter-and-2009-Financial-Results-744973http://www.finanzen.net/nachricht/Alnylam-Receives-Notice-of-Allowance-from-United-States-Patent-and-Trademark-Office-for-New-Patent-Broadly-Covering-RNAi-Therapeutics-739150 <style type="text/css"> <!-- .bwlistitemmarginbottom {margin-bottom: 10.0px} .bwtextaligncenter {text-align: center} --> </style> <!-- sh_cad_1 --> Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, ...http://www.finanzen.net/nachricht/Alnylam-Receives-Notice-of-Allowance-from-United-States-Patent-and-Trademark-Office-for-New-Patent-Broadly-Covering-RNAi-Therapeutics-739150